🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. NAT01, NAT03, Placebo film coated tablets, NAT02

    Dr. Falk Pharma GmbH

    Idiopathic or Diabetic Gastroparesis

    phase 2 small molecule active

    1 trial

  2. NMD670, NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  3. NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Charcot-Marie-Tooth Disease Type 1 and Type 2

    phase 2 small molecule active

    1 trial

  4. NOE-105, Placebo, Hard Capsules

    Lacuna Pharma Pty Ltd

    Tourette Syndrome

    phase 2 small molecule active

    1 trial

  5. NS-229 matching tablets with no active treatment, NS-229

    Lacuna Pharma Pty Ltd

    Eosinophilic granulomatosis with polyangiitis (EGPA)

    phase 2 small molecule active

    1 trial

  6. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  7. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  8. NX210c, GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  9. NXC-201 CAR-T

    Immix Biopharma

    Light Chain (AL) Amyloidosis

    phase 2 mab active

    1 trial

  10. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  11. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Glioblastoma

    phase 2 small molecule active

    1 trial

  12. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    NMO Spectrum Disorder

    phase 2 small molecule terminated

    1 trial

  13. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  14. Namodenoson 25mg

    Can-Fite BioPharma

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  16. Nebulized IVX-0142

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule completed

    1 trial

  17. Neflamapimod

    Lacuna Pharma Pty Ltd

    Dementia with Lewy Bodies (DLB)

    phase 2 small molecule active

    1 trial

  18. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  19. Ninerafaxstat, Tablet, identical in appearance to ninerafaxstat tablets

    Lacuna Pharma Pty Ltd

    Non-obstructive hypertrophic cardiomyopathy

    phase 2 small molecule active

    1 trial

  20. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  21. Normix 200 mg compresse rivestite con film, The placebo is a film-coated oral tablet designed to be comparable in appearance, administration, and handling to the investigational medicinal product (rifaximin 200 mg film-coated tablets), while containing no active pharmaceutical ingredient. The placebo consists exclusively of commonly used pharmaceutical excipients with established safety profiles and is administered solely to maintain blinding in the clinical trial.

    Fondazione Telethon ETS

    substance use disorder

    phase 2 small molecule active

    1 trial

  22. Novo Nordisk GlucaGen®

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  23. OCALIVA, Placebo for Bezafibrate, Bezalip Mono, Placebo for Obeticholic Acid, Bezalip, OCALIVA

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  24. OCTREOTIDE ACETATE, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Carcinoid Syndrome

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources